Treatments Archives - Pulmonology Advisor

Update Confirms DFS Benefit With Osimertinib in EGFR-Mutated, Resected NSCLC

By

September 27, 2022

Adjuvant osimertinib continues to demonstrate a disease-free survival benefit vs placebo in resected, stage IB-IIIA, EGFR-mutated non-small cell lung cancer.

General Medicine

COVID-19 Treatment: WHO Releases 11th Update to Living Guideline

By

Devon Cimino

September 26, 2022

The World Health Organization describes new recommended treatments for COVID-19 in the 11th update to their living guideline.

Pneumonia

Macrolides With Ampicillin vs Ceftriaxone for Community-Acquired Pneumonia

By

Jessica Nye, PhD

September 21, 2022

Researchers compared the effects of macrolides in combination with either ampicillin or ceftriaxone among patients hospitalized with community-acquired pneumonia.

Doctor examining patients lungs, back, chest exam

General Pulmonology

Eteplirsen Delays Pulmonary Decline in Duchenne Muscular Dystrophy

By

Sheila Jacobs

September 20, 2022

Using new data sources, researchers evaluated the effect of eteplirsen on pulmonary function over time in patients with Duchenne muscular dystrophy.

Lung Cancer

How Do Patients With Lung Cancer Report on the Quality of Care?

By

Steve Fiorillo

September 19, 2022

As lung cancer is one of the most common forms of cancer, understanding patient needs and listening to their experience of whether they are being met can help the quality of care in hundreds of thousands of patients. What have recent studies suggested about patient experiences with lung cancer care, and what improvements have been made?

Tuberculosis

Dolutegravir Twice Daily Optimal for Children With HIV-Associated Tuberculosis on Rifampicin

By

Bradley van Paridon

September 7, 2022

Researchers assessed the safety and effectiveness of twice-daily dolutegravir dosing plus rifampicin in children with HIV-associated tuberculosis infection.

Lung Cancer

Gefitinib Plus Chemo Improves PFS2 Over Gefitinib Alone in EGFR-Mutant NSCLC

By

Jonathan Goodman, MPhil

August 30, 2022

Patients who received gefitinib plus platinum chemotherapy had significantly longer PFS2 than patients who received gefitinib alone.

General Medicine

Rates of Severe COVID-19 Lower With Nirmatrelvir in Adults Aged 65 Years or Older

August 30, 2022

For adults aged 65 years or older, nirmatrelvir is associated with reduced rates of hospitalization and death due to COVID-19.

General Medicine

Tecovirimat Well Tolerated for Treatment of Monkeypox

August 29, 2022

Compassionate use of tecovirimat is well tolerated for the treatment of monkeypox, according to a research letter published online.

$It is unclear whether disease control prevents RA-related bone loss, but data suggest it does in patients with early RA and high disease activity.1 Two systemic analyses of RA studies concluded that biologic DMARDs reduce generalized and localized bone loss.2,19 However, few studies were phase 3 trials, and most measured markers of bone turnover.2,19 High-quality trials that measure BMD change or fracture risk are needed. Bisphosphonates, denosumab, and parathyroid hormone are agents approved for osteoporosis and glucocorticoid-induced osteoporosis. Bisphosphonates and denosumab appear to have similar efficacy at preserving BMD.1 In some RA studies, denosumab also prevented and repaired erosions.2 The ACR guidelines for glucocorticoid-induced osteoporosis categorize patients as having low, moderate, or high fracture risk.18 They recommend calcium (1000 to 1200 mg/d) and vitamin D (600 to 800 IU/d) supplements for all patients, plus an osteoporosis agent (preferably an oral bisphosphonate) for patients with moderate to high fracture risk.$

Pneumonia

Corticosteroid Dose Predicts Mortality in Rheumatic Diseases Plus Pneumonia

By

Maria Arini Lopez, PT, DPT, CSCS, CMTPT

August 24, 2022

Researchers assessed the effect of adjunctive corticosteroid therapy on mortality outcomes in patients with rheumatic diseases complicated by Pneumocystis jirovicii pneumonia.